Top 10 Companies in the Oligonucleotide Market (2026): Market Leaders Powering Global Therapeutics

MARKET INSIGHTS

The Global oligonucleotide market was valued at USD 1.18 billion in 2025 and is projected to reach USD 2.42 billion by 2034, exhibiting a Compound Annual Growth Rate (CAGR) of 10.6% during the forecast period.

Oligonucleotides are short, single‑stranded DNA or RNA molecules typically consisting of 20 to 30 nucleotides. These molecules play a crucial role in various biotechnological and therapeutic applications, including gene silencing, diagnostics, and drug development. The increasing prevalence of genetic disorders and the growing demand for personalized medicine are key drivers for market growth.

Market expansion is further supported by advancements in synthesis technologies and the declining cost of oligonucleotide production. North America currently holds the largest market share due to high R&D investments and the presence of key market players. However, the Asia‑Pacific region is expected to witness the highest growth rate during the forecast period, driven by increasing healthcare expenditure and growing biopharmaceutical sector.

Key applications driving demand include antisense oligonucleotides (ASOs) for therapeutic use, small interfering RNAs (siRNAs) for gene silencing, and CRISPR‑associated proteins for gene editing. The COVID‑19 pandemic also accelerated demand for oligonucleotides in vaccine development and diagnostic testing.

Oligonucleotide Market – View in Detailed Research Report

REGIONAL ANALYSIS

North America accounted for 42% of Global market revenue in 2023, with the United States being the largest contributor. Europe follows with 28% market share, led by Germany, France, and the UK. Asia‑Pacific shows the fastest growth rate at 12.3% CAGR, driven by increasing biopharmaceutical investments in China and India.

TOP 10 Companies in the Oligonucleotide Market

🔟 1. Thermo Fisher Scientific

Headquarters: Waltham, Massachusetts, USA
Key Offering: Custom DNA synthesis, modified RNA, high‑throughput library preparation kits, and nucleic‑acid therapeutics.

Thermo Fisher Scientific remains the undisputed leader in the oligonucleotide market, offering a broad portfolio that spans research, diagnostics, and therapeutic development. Their automated manufacturing platform enables rapid scale‑up and high‑quality production of both short‑ and long‑chain oligos.

Sustainability & Growth Initiatives:

• Strategic partnership with Singapore‑based biotech to develop novel oligonucleotide‑based therapies.
• Investment in solid‑phase synthesis automation to reduce lead times.
• Commitment to expanding GMP‑grade production capacity in Asia‑Pacific.

🗹 2. Merck KGaA

Headquarters: Darmstadt, Germany
Key Offering: High‑purity phosphoramidites, specialty oligonucleotides, and RNA therapeutics.

Merck leverages its chemical synthesis expertise to supply critical reagents for oligonucleotide production, supporting both academic research and commercial drug development.

Sustainability & Growth Initiatives:

• Expansion of GMP‑compliant manufacturing in Germany and the US.
• R&D collaboration with biotech startups focused on antisense therapies.
• Investments in environmentally friendly synthesis processes.

🗹 3. Agilent Technologies

Headquarters: Santa Clara, California, USA
Key Offering: Microarray reagents, next‑generation sequencing (NGS) kits, and diagnostic oligonucleotides.

Agilent’s strong presence in diagnostics and sequencing positions it as a key supplier of oligonucleotide probes for genomic and transcriptomic applications.

Sustainability & Growth Initiatives:

• Development of low‑waste synthesis protocols.
• Expansion of NGS library prep services in emerging markets.
• Partnerships with academic institutions to accelerate biomarker discovery.

🗹 4. Eurofins Scientific

Headquarters: Luxembourg City, Luxembourg
Key Offering: Fast‑turnaround oligonucleotide synthesis, GMP‑grade production, and analytical services.

Eurofins provides rapid custom synthesis and high‑quality testing, making it a preferred partner for biotech firms and pharmaceutical companies.

Sustainability & Growth Initiatives:

• Expansion of contract manufacturing facilities in Asia‑Pacific.
• Investment in green chemistry initiatives.
• Strategic alliances with CROs to broaden service offerings.

🗹 5. Bachem

Headquarters: Balgach, Switzerland
Key Offering: GMP‑compliant oligonucleotide manufacturing, specialty reagents, and process development.

Bachem’s expertise in GMP production supports the manufacturing of clinical‑grade oligonucleotides for drug candidates.

Sustainability & Growth Initiatives:

• Expansion of production capacity in Europe and the US.
• Investment in renewable energy for manufacturing sites.
• Collaborations with pharma to co‑develop next‑generation therapies.

🗹 6. Sumitomo Chemical

Headquarters: Tokyo, Japan
Key Offering: Phosphorothioate backbone chemistry, nuclease‑resistant oligonucleotides, and delivery platforms.

Sumitomo’s innovative backbone modifications enhance stability and efficacy of therapeutic oligos.

Sustainability & Growth Initiatives:

• Partnerships with Japanese biotech firms to develop antisense therapeutics.
• Investment in scalable synthesis equipment for high‑throughput production.
• Commitment to reducing carbon footprint of manufacturing processes.

🗹 7. OligoFactory

Headquarters: Austin, Texas, USA
Key Offering: Proprietary solid‑phase synthesis platform, rapid custom oligo delivery, and specialty chemistries.

OligoFactory differentiates itself with proprietary synthesis chemistry that reduces side‑product formation, enabling higher purity and faster turnaround.

Sustainability & Growth Initiatives:

• Expansion of on‑demand synthesis capabilities.
• Collaboration with academic labs for early‑stage discovery.
• Implementation of waste‑reduction protocols.

🗹 8. Sylentis

Headquarters: Paris, France
Key Offering: Antisense and aptamer platforms for targeted drug development.

Sylentis focuses on delivering chemically stabilized oligonucleotides for rare disease and oncology indications.

Sustainability & Growth Initiatives:

• Strategic alliance with global pharma for pipeline development.
• Investment in scalable manufacturing for large‑scale production.
• Commitment to sustainable sourcing of raw materials.

🗹 9. Roche NimbleGen

Headquarters: Basel, Switzerland
Key Offering: Custom library services for CRISPR and RNA‑seq applications.

Roche NimbleGen provides bespoke oligonucleotide libraries for genome editing and transcriptomic research.

Sustainability & Growth Initiatives:

• Expansion of CRISPR‑related services in emerging markets.
• Partnerships with biotech incubators to foster innovation.
• Implementation of eco‑friendly manufacturing practices.

🗹 10. PerkinElmer

Headquarters: Shelton, Connecticut, USA
Key Offering: Advanced analytical instruments, NGS reagents, and custom oligonucleotide synthesis.

PerkinElmer supports the oligonucleotide market through high‑precision analytical tools and rapid synthesis services.

Sustainability & Growth Initiatives:

• Development of low‑energy consumption synthesis equipment.
• Expansion of services in Asia‑Pacific and Latin America.
• Collaborations with academic institutions to advance personalized medicine.

Download FREE Sample Report

Get Full Report

FUTURE OUTLOOK

The oligonucleotide market shows strong growth potential with increasing applications in personalized medicine and genetic research. Technological advancements in synthesis and purification are expected to further reduce production costs. However, regulatory challenges and high development costs remain key challenges for market players.

The market is also witnessing increased investment in RNA‑based therapeutics, with several products in advanced clinical trials. This trend is expected to continue, particularly in oncology and rare disease treatment applications.

FUTURE TRENDS

1️⃣ Emerging Applications in CRISPR‑Based Gene Editing – The demand for guide RNA oligonucleotides is growing as CRISPR therapeutics move from bench to bedside. Companies delivering chemically stabilized guides at competitive prices are poised to capture this niche.

2️⃣ Advancements in Diagnostics – Oligonucleotide‑based diagnostic tools, such as rapid PCR tests and NGS library prep, are gaining prominence. The COVID‑19 pandemic demonstrated their effectiveness, and this trend is expected to continue with a focus on point‑of‑care solutions.

3️⃣ Focus on Personalized Medicine – Therapies tailored to individual genetic profiles maximize efficacy and minimize adverse reactions. The growing availability of genomic data fuels the development of customized oligonucleotide solutions.

4️⃣ Increasing Regulatory Scrutiny – Regulatory bodies worldwide are enhancing scrutiny of oligonucleotide therapies to ensure safety and efficacy. This leads to more rigorous clinical trials and approval processes, ultimately improving product quality and reliability.